Sun.Apr 20, 2025

article thumbnail

Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria

Covalent Modifiers

Genhui Xiao, Yumeng Cui, Liangliang Zhou, Chuya Niu, Bing Wang, Jinglan Wang, Shaoyang Zhou, Miaomiao Pan, Chi Kin Chan, Yan Xia, Lan Xu, Yu Lu, Shawn Chen mLife , 2025 DOI: [link] The caseinolytic protease complex ClpP1P2 is crucial for protein homeostasis in mycobacteria and stress response and virulence of the pathogens. Its role as a potential drug target for combating tuberculosis (TB) has just begun to be substantiated in drug discovery research.

article thumbnail

Child Concussion: What To Know If Your Child Takes a Blow To the Head

Drugs.com

SUNDAY, April 20, 2025 When a child tumbles to the floor from a blow to the head, a parent's inner alarms should sound. The child may have a brain injury. Here's what parents need to know:What is a concussion?A concussion is a mild traumatic b.

232
232
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tegomil fumarate

New Drug Approvals

Tegomil fumarate cas 1817769-42-8 dimethyl (2E,19E)-4,18-dioxo-5,8,11,14,17-pentaoxahenicosa-2,19-diene-1,21-dioate 4- O -[2-[2-[2-[2-[( E )-4-methoxy-4-oxobut-2-enoyl]oxyethoxy]ethoxy]ethoxy]ethyl] 1- O -methyl ( E )-but-2-enedioate 1,21-Dimethyl (2E,19E)-4,18-dioxo-5,8,11,14,17-pentaoxaheneicosa-2,19-dienedioate 5,8,11,14,17-Pentaoxaheneicosa-2,19-dienedioic acid, 4,18-dioxo-, 1,21-dimethyl ester, (2E,19E)- Chemical Formula: C18H26O11 Exact Mass: 418.15 Molecular Weight: 418.395 Elemental Anal

62
article thumbnail

Where Does Rare Disease and Patient-Focus Fall into Commissioner Makary’s Priorities & the MAHA Platform for FDA? A New Ultrarare Approval Pathway & More

FDA Law Blog: Drug Discovery

By Dr. Naomi Lowy, Principal Drug Regulatory Expert & James E. Valentine There is much change happening at FDA. In the wake of the April 1 st reduction in force, there has been a great deal of uncertainty about what the impacts will be. This rings particularly true amongst the rare disease patient community, along with many small biotech companies (and their investors) that take on the risk of developing orphan drugs for exceedingly small patient populations.

FDA 89
article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!